Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Bagsværd, Denmark Wednesday, March 12, 2025, 12:00 Hrs [IST] ...
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
Zacks Investment Research on MSN3d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous ...
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
The REDEFINE 2 trial (ClinicalTrials.gov Identifier: NCT05394519) evaluated the efficacy and safety of CagriSema in 1206 obese or overweight adults aged 18 years and older with type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback